Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ependymoma × neratinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Neoplasm Metastasis 10 Neoplasms 7 Brain Neoplasms 4 HER2-positive Breast Cancer 3 Carcinoma, Non-Small-Cell Lung 3 Advanced Malignant Solid Tumors 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Lung Neoplasms 2 Colorectal Neoplasms 2 Uterine Cervical Neoplasms 1 Thrombocytosis 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Recurrence 1 Rare Tumour 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Meningioma 1

Interventions

Temozolomide 26 Magnetic Resonance Spectroscopy 16 Etoposide 13 Cyclophosphamide 13 Filgrastim 10 Radiotherapy 9 Carboplatin 9 Bevacizumab 9 Biopsy 8 X-Rays 6 Thiotepa 6 Specimen Handling 6 Phantoms, Imaging 6 Cisplatin 6 Nuclear Medicine Department, Hospital 5 Nivolumab 5 Irinotecan 5 Carmustine 5 sargramostim 4 Vincristine 4 Radiation 4 Peripheral Blood Stem Cell Transplantation 4 Methotrexate 4 Erlotinib Hydrochloride 4 etoposide phosphate 3 Surveys and Questionnaires 3 Lapatinib 3 Granulocyte Colony-Stimulating Factor 3 Gadolinium DTPA 3 Azacitidine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04374305 2026-01-12

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Active not recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡